Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Investing Activities (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Cash from Investing Activities for 6 consecutive years, with $451000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 495.61% year-over-year to $451000.0, compared with a TTM value of $136000.0 through Sep 2025, up 129.5%, and an annual FY2024 reading of -$892000.0, up 83.52% over the prior year.
  • Cash from Investing Activities was $451000.0 for Q3 2025 at Barinthus Biotherapeutics, up from -$32000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $451000.0 in Q3 2025 and bottomed at -$12.2 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is -$1.3 million, with a median of -$278000.0 recorded in 2024.
  • The sharpest move saw Cash from Investing Activities crashed 6151.28% in 2021, then surged 495.61% in 2025.
  • Year by year, Cash from Investing Activities stood at -$12.2 million in 2021, then skyrocketed by 95.19% to -$586000.0 in 2022, then soared by 126.11% to $153000.0 in 2023, then crashed by 281.7% to -$278000.0 in 2024, then surged by 262.23% to $451000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for BRNS at $451000.0 in Q3 2025, -$32000.0 in Q2 2025, and -$5000.0 in Q1 2025.